Memantine

Hot Sale Professional Pharmaceutical Intermediate Memantine CAS 19982-08-2

 

  • Isem tal-prodott:

    Memantine

  • Grad:

    Grad farmaċewtiku

  • Proprjetajiet:

    Trab abjad

  • Ippakkjar:

    25kg/tanbur

  • MOQ:

    1 ton

  • Ħażna:Kessaħ Post Niexef
  • Żmien kemm idum tajjeb:2 snin


Dettalji

Tikketti

Deskrizzjoni tal-prodott

 

Memantine hydrochloride is a raw material. It should be prescribed by experienced doctors in the diagnosis and treatment of Alzheimer's dementia and guided by patients. Treatment can only begin when there are caregivers around the patient who regularly supervise the patient's medication. Dementia should be diagnosed in accordance with current diagnostic criteria and guidelines.

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003.
 It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Wiri tal-Prodott

 

Karatteristiċi

 

Memantine is clinically used for the treatment of moderate to severe senile dementia and parkinsonism syndrome. It is a new type of anti-senile dementia drug and can be used for the treatment of moderate to severe senile dementia.

Applikazzjoni

 

Memantine is used to treat moderate-to-severe Alzheimer's disease, especially for people who are intolerant of or have a contraindication to AChE (acetylcholinesterase) inhibitors.One guideline recommends memantine or an AChE inhibitor be considered in people in the early-to-mid stage of dementia.

Memantine has been associated with a modest improvement; with small positive effects on cognition, mood, behavior, and the ability to perform daily activities in moderate-to-severe Alzheimer's disease. There does not appear to be any benefit in mild disease.

Memantine when added to donepezil in those with moderate-to-severe dementia resulted in "limited improvements" in a 2017 review. The UK National Institute of Clinical Excellence (NICE) issued guidance in 2018 recommending consideration of the combination of memantine with donepezil in those with moderate-to-severe dementia. Effects in autism are unclear. Recent scientific journal reports are showing guarded promise with severe obsessive compulsive disorder.

 

Vantaġġi

 

Għandna ħafna fabbriki ta 'kwalità għolja b'kooperazzjoni profonda, li jistgħu jagħtuk prodotti ta' kwalità għolja u prezzijiet kompetittivi. U nistgħu wkoll nagħtu skontijiet għal xiri bl-ingrossa. U aħna nikkooperaw ma 'ħafna kumpaniji professjonali tal-ġarr tal-merkanzija, nistgħu nwasslu prodotti b'mod sikur u bla xkiel f'idejk. Il-ħin tal-kunsinna huwa ta 'madwar 3-20 jum wara l-konferma tal-ħlas.

Speċifikazzjoni

 

Oġġett

Requirements

Test Results

appearance

White or almost white crystalline powder 

White crystalline powder 

Identifikazzjoni

IR 

Comply 

Related substance 

1-methyladamantane ≤0.3%

1,3,5 -trimethyladamantane ≤0.3%

Unknow impuritiy     ≤0.1%

Total impurity ≤0.5%

0.13%

0.14%

<0.1%

<0.4%

Residwu mat-tqabbid 

≤0.1% 

0.06%

Heavy matal 

≤10ppm 

<10ppm 

Telf fuq tnixxif 

≤0.5%

0.29%

Assaġġ

98.5-101.0%

99.13%

Residual

Solvents

Ethyl Acetat: ≤0.5%

Ethanol: ≤0.5%

0.08%

0.12%

PH

4.5-5.5 

5.3

Microbial Limits

Max 5*102 aerobes and fungl per 1g 

E. Coli: Negative Salmonella: Negative

 

Pass 

Size of distributed particles 

Pass 100μ m

Jikkonforma

Konklużjoni

Meet the requirements 

 

Għarfien tal-prodott:

 

Memantine is a medication used to treat moderate-to-severe Alzheimer's disease. It is less preferred than acetylcholinesterase inhibitors such as donepezil. Treatment should only be continued if beneficial effects are seen. It is taken by mouth.
Memantine was approved for medical use in the United States in 2003.
 It is available as a generic medication. In 2017, it was the 149th most commonly prescribed medication in the United States, with more than four million prescriptions

Memantine HCl is the HCl form of Memantine. Memantine is a well- known neuroprotective drug used for the treatment of Alzheimer's disease. It is believed to be the first neuroprotective drug that has achieve clinical approval by US FDA as well as European.
The development of Alzheimer's disease involves the misfolded mutant proteins such as β-amyloid peptide (Aβ, particularly Aβ1−42). These misfolded mutant protein can increase the NMDA response and further cause severe excitotoxicity.
Memantine suppresses this process through acting as the antagonist of the N-methyl-d- aspartate-sensitive glutamate receptor (NMDARs).
Memantine is also under investigation as a potential treatment for other kind of neurodegenerative disorders such as HIV-associated dementia, neuropathic pain, glaucoma, depression, Huntington's disease, ALS and movement disorders, among other. 

 

Tbaħħir u ħlas

 

 

 

FAQ

 

1. Inti fabbrika jew kumpanija kummerċjali?
Aħna kumpanija li tintegra l-industrija u l-kummerċ, li nipprovdu servizz one-stop. OEM jista 'jiġi aċċettat.

2. Inti tipprovdi kampjuni? Huwa b'xejn jew żejjed?
Kampjuni b'xejn. It-tariffa tal-merkanzija tal-kampjun trid titħallas min-naħa tiegħek.

3. Għandek xi ċertifikati relatati mal-kontroll tal-kwalità?
Ċertifikazzjoni ISO 9001:2008 biex tiġi żgurata l-kwalità.

4. X'għandi nipprovdi biex tikseb kwotazzjoni?
PLS għarrafna bit-tip ta 'prodott li għandek bżonn, kwantità tal-ordni, indirizz u rekwiżiti speċifiċi. Il-kwotazzjoni ssir għar-referenza tiegħek fil-ħin.

5. X'tip ta 'metodu ta' ħlas tippreferi? X'tip ta' termini huma aċċettati?
Termini ta ' Kunsinna Aċċettati: FOB, CFR, CIF, EXW;
Munita ta 'Ħlas Aċċettata: USD;
Tip ta' Ħlas Aċċettat: T/T,Western Union; Paypal, Assigurazzjoni tal-Kummerċ.
Lingwa Mitkellma: Ingliż.

 

Jekk inti interessat fil-prodotti tagħna, tista 'tagħżel li tħalli l-informazzjoni tiegħek hawn, u aħna ser inkunu f'kuntatt miegħek dalwaqt.


Ikteb il-messaġġ tiegħek hawn u ibgħatilna